This statistic shows the number of registrations of newly diagnosed cases of colon cancer in England in 2022, by age group and gender. The group most affected by colon cancer was men aged 75 to 79 years, with *** thousand cases registered. It should, of course, be noted that the number of people in England in each age group varies and is therefore not necessarily a reflection of susceptibility to colon cancer.

In 2022, 55.8 males and 44.3 females per 100,000 population in England were registered as newly diagnosed with colon cancer. The rate of both females and males registered as newly diagnosed with colon cancer considerably decreased from the previous year. This statistic shows the rate of newly diagnosed cases of colon cancer per 100,000 population in England from 1995 to 2022, by gender.

Cancer was responsible for around *** deaths per 100,000 population in the United States in 2023. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated ****** deaths among men alone in 2025. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as ** percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around ** percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. Other modifiable risk factors for cancer include being obese, drinking alcohol, and sun exposure.

Medical Service Study Areas (MSSAs)As defined by California's Office of Statewide Health Planning and Development (OSHPD) in 2013, "MSSAs are sub-city and sub-county geographical units used to organize and display population, demographic and physician data" (Source). Each census tract in CA is assigned to a given MSSA. The most recent MSSA dataset (2014) was used. Spatial data are available via OSHPD at the California Open Data Portal. This information may be useful in studying health equity.Age-Adjusted Incidence Rate (AAIR)Age-adjustment is a statistical method that allows comparisons of incidence rates to be made between populations with different age distributions. This is important since the incidence of most cancers increases with age. An age-adjusted cancer incidence (or death) rate is defined as the number of new cancers (or deaths) per 100,000 population that would occur in a certain period of time if that population had a 'standard' age distribution. In the California Health Maps, incidence rates are age-adjusted using the U.S. 2000 Standard Population.Cancer incidence ratesIncidence rates were calculated using case counts from the California Cancer Registry. Population data from 2010 Census and SEER 2015 census tract estimates by race/origin (controlling to Vintage 2015) were used to estimate population denominators. Yearly SEER 2015 census tract estimates by race/origin (controlling to Vintage 2015) were used to estimate population denominators for 5-year incidence rates (2013-2017)According to California Department of Public Health guidelines, cancer incidence rates cannot be reported if based on <15 cancer cases and/or a population <10,000 to ensure confidentiality and stable statistical rates.Spatial extent: CaliforniaSpatial Unit: MSSACreated: n/aUpdated: n/aSource: California Health MapsContact Email: gbacr@ucsf.eduSource Link: https://www.californiahealthmaps.org/?areatype=mssa&address=&sex=Both&site=AllSite&race=&year=05yr&overlays=none&choropleth=Obesity

BackgroundThere are limited colonoscopy-based cohort data concerning the effectiveness of colonoscopy in reducing colorectal cancer deaths. The aim of this study was to clarify whether colonoscopy reduces colorectal cancer mortality.MethodsA cohort of 18,816 patients who underwent colonoscopy without a diagnosis of colorectal cancer between 2001 and 2010 at high colonoscopy procedure volume centers was selected. Patient characteristics and colonoscopy findings were assessed. The main endpoint was colorectal cancer death (all, right-sided, and left-sided cancers), and data were censored at the time of the final visit or the final colonoscopy. The standardized all colorectal, colon, and rectal cancer mortality rates were estimated with reference to those of the general Japanese population. Additional outcome was all- cause death and the standardized all-cause mortality rate was also estimated.ResultsThe total observed person-year mortality for colorectal cancer was 67,119. Of these, 4, 3, and 1 patients died from colorectal, colon, and rectal cancers, respectively; these values were significantly lower than the number of expected deaths in the general population, estimated to be 53.1, 34.0, and 19.1, respectively. The standardized mortalities for all colorectal, colon, and rectal cancers were 0.08 (95% confidence interval (CI), 0.02–0.17), 0.09 (95% CI, 0.02–0.22), and 0.05 (95% CI, 0.0002–0.21), respectively. There were 586 all-cause deaths (3.11%) during the observation period. The standardized all-cause mortality ratios were 0.22 (95% CI, 0.206–0.23).ConclusionsThe colorectal cancer mortality of patients who received colonoscopy without colorectal cancer diagnosis decreased significantly compared with that of individuals in the general population. These results were compatible even in patients with right-sided colon cancer.

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

Mortality from colorectal cancer (ICD-10 C17-C21 equivalent to ICD-9 152-154). To reduce deaths from colorectal cancer. Legacy unique identifier: P00225

In 2018, Hungary reported ***** new colorectal cancer cases per 100,000 population, the highest incidence in Europe. This was followed by an incidence rate of **** colorectal cancer cases in Portugal. While in Denmark, **** colorectal cancer cases per 100,000 inhabitants were diagnosed in that year.

BackgroundColorectal cancer (CRC) incidence rates have increased in younger individuals worldwide. We examined the most recent early- and late-onset CRC rates for the US.MethodsAge-standardized incidence rates (ASIR, per 100,000) of CRC were calculated using the US Cancer Statistics Database’s high-quality population-based cancer registry data from the entire US population. Results were cross-classified by age (20-49 [early-onset] and 50-74 years [late-onset]), race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, American Indian/Alaskan Native, Asian/Pacific Islander), sex, anatomic location (proximal, distal, rectal), and histology (adenocarcinoma, neuroendocrine).ResultsDuring 2001 through 2018, early-onset CRC rates significantly increased among American Indians/Alaskan Natives, Hispanics, and Whites. Compared to Whites, early-onset CRC rates are now 21% higher in American Indians/Alaskan Natives and 6% higher in Blacks. Rates of early-onset colorectal neuroendocrine tumors have increased in Whites, Blacks, and Hispanics; early-onset colorectal neuroendocrine tumor rates are 2-times higher in Blacks compared to Whites. Late-onset colorectal adenocarcinoma rates are decreasing, while late-onset colorectal neuroendocrine tumor rates are increasing, in all racial/ethnic groups. Late-onset CRC rates remain 29% higher in Blacks and 15% higher in American Indians/Alaskan Natives compared to Whites. Overall, CRC incidence was higher in men than women, but incidence of early-onset distal colon cancer was higher in women.ConclusionsThe early-onset CRC disparity between Blacks and Whites has decreased, due to increasing rates in Whites—rates in Blacks have remained stable. However, rates of colorectal neuroendocrine tumors are increasing in Blacks. Blacks and American Indians/Alaskan Natives have the highest rates of both early- and late-onset CRC.ImpactOngoing prevention efforts must ensure access to and uptake of CRC screening for Blacks and American Indians/Alaskan Natives.

Rate: Number of new cases (per 100,000) of invasive colorectal cancer diagnosed.

Definition: Age-adjusted incidence rate of cancer of the colon and rectum per 100,000 population (ICD-O-3 codes: C18.0-C20.9 excl. types 9590-9992).

Data Source: New Jersey State Cancer Registry, Cancer Epidemiology Services, New Jersey Department of Health

Medical Service Study Areas (MSSAs)As defined by California's Office of Statewide Health Planning and Development (OSHPD) in 2013, "MSSAs are sub-city and sub-county geographical units used to organize and display population, demographic and physician data" (Source). Each census tract in CA is assigned to a given MSSA. The most recent MSSA dataset (2014) was used. Spatial data are available via OSHPD at the California Open Data Portal. This information may be useful in studying health equity.Age-Adjusted Incidence Rate (AAIR)Age-adjustment is a statistical method that allows comparisons of incidence rates to be made between populations with different age distributions. This is important since the incidence of most cancers increases with age. An age-adjusted cancer incidence (or death) rate is defined as the number of new cancers (or deaths) per 100,000 population that would occur in a certain period of time if that population had a 'standard' age distribution. In the California Health Maps, incidence rates are age-adjusted using the U.S. 2000 Standard Population.Cancer incidence ratesIncidence rates were calculated using case counts from the California Cancer Registry. Population data from 2010 Census and SEER 2015 census tract estimates by race/origin (controlling to Vintage 2015) were used to estimate population denominators. Yearly SEER 2015 census tract estimates by race/origin (controlling to Vintage 2015) were used to estimate population denominators for 5-year incidence rates (2013-2017)According to California Department of Public Health guidelines, cancer incidence rates cannot be reported if based on <15 cancer cases and/or a population <10,000 to ensure confidentiality and stable statistical rates.Spatial extent: CaliforniaSpatial Unit: MSSACreated: n/aUpdated: n/aSource: California Health MapsContact Email: gbacr@ucsf.eduSource Link: https://www.californiahealthmaps.org/?areatype=mssa&address=&sex=Both&site=AllSite&race=&year=05yr&overlays=none&choropleth=Obesity

Rate: Number of deaths due to a cancer of the colon, rectum, or anus per 100,000 population.

Definition: Number of deaths per 100,000 with malignant neoplasm (cancer) of the colon, rectum, or anus as the underlying cause (ICD-10 codes: C18-C21).

Data Sources:

(1) Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File. CDC WONDER On-line Database accessed at http://wonder.cdc.gov/cmf-icd10.html

(2) Death Certificate Database, Office of Vital Statistics and Registry, New Jersey Department of Health

(3) Population Estimates, State Data Center, New Jersey Department of Labor and Workforce Development

Years of life lost due to mortality from colorectal cancer (ICD-10 C17-C21). Years of life lost (YLL) is a measure of premature mortality. Its primary purpose is to compare the relative importance of different causes of premature death within a particular population and it can therefore be used by health planners to define priorities for the prevention of such deaths. It can also be used to compare the premature mortality experience of different populations for a particular cause of death. The concept of years of life lost is to estimate the length of time a person would have lived had they not died prematurely. By inherently including the age at which the death occurs, rather than just the fact of its occurrence, the calculation is an attempt to better quantify the burden, or impact, on society from the specified cause of mortality. Legacy unique identifier: P00201

BackgroundRecent studies reported an increase in colorectal cancer incidence for adults below 50 years. There is a lack of studies distinguishing between histological subgroups, especially from Europe.MethodsUsing data from the Bavarian Cancer Registry, we analyzed incidence trends in colorectal cancer by age (20–29, 30–39, 40–49, and 50 years and above), anatomic site (colon without appendix, appendix, and rectum), and histological subgroup (adenocarcinoma and neuroendocrine neoplasm) from 2005 to 2019. We calculated 3-year average annual age-standardized incidence rates (ASIR) per 100,000 persons for the beginning (2005–2007) and the end (2017–2019) of the study period and estimated average annual percentage change.ResultsData from 137,469 persons diagnosed with colorectal cancer were included. From 139,420 cases in total, 109,825 (78.8%) were adenocarcinomas (ACs), 2,800 (2.0%) were neuroendocrine neoplasms (NENs), and 26,795 (19.2%) had other histologies. This analysis showed a significant increase in the 3-year average annual ASIR of colorectal NENs in all age groups between 2005–2007 and 2017–2019 with the highest increase in the age groups 30–39 years (0.47 to 1.53 cases per 100,000 persons; +226%; p < 0.05) and 20–29 years (0.52 to 1.38 cases per 100,000 persons; +165%; p < 0.05). The increase was driven by appendiceal and rectal NENs but not by colonic NENs. The 3-year average annual ASIR of colorectal ACs did not change significantly for the age groups below 50 years. For those aged 50 years and above, the 3-year average annual ASIR of colorectal ACs decreased significantly (132.55 to 105.95 cases per 100,000 persons; −20%; p < 0.05]). The proportion of NENs increased across all age groups, especially in the younger age groups.ConclusionFuture studies that analyze trends in early-onset colorectal cancer need to distinguish between anatomic sites as well as histological subgroups and may, thus, provide useful information regarding the organization of colorectal cancer screening, which primarily helps to detect adenomas and adenocarcinomas."

Medical Service Study Areas (MSSAs)As defined by California's Office of Statewide Health Planning and Development (OSHPD) in 2013, "MSSAs are sub-city and sub-county geographical units used to organize and display population, demographic and physician data" (Source). Each census tract in CA is assigned to a given MSSA. The most recent MSSA dataset (2014) was used. Spatial data are available via OSHPD at the California Open Data Portal. This information may be useful in studying health equity.Age-Adjusted Incidence Rate (AAIR)Age-adjustment is a statistical method that allows comparisons of incidence rates to be made between populations with different age distributions. This is important since the incidence of most cancers increases with age. An age-adjusted cancer incidence (or death) rate is defined as the number of new cancers (or deaths) per 100,000 population that would occur in a certain period of time if that population had a 'standard' age distribution. In the California Health Maps, incidence rates are age-adjusted using the U.S. 2000 Standard Population.Cancer incidence ratesIncidence rates were calculated using case counts from the California Cancer Registry. Population data from 2010 Census and SEER 2015 census tract estimates by race/origin (controlling to Vintage 2015) were used to estimate population denominators. Yearly SEER 2015 census tract estimates by race/origin (controlling to Vintage 2015) were used to estimate population denominators for 5-year incidence rates (2013-2017)According to California Department of Public Health guidelines, cancer incidence rates cannot be reported if based on <15 cancer cases and/or a population <10,000 to ensure confidentiality and stable statistical rates.Spatial extent: CaliforniaSpatial Unit: MSSACreated: n/aUpdated: n/aSource: California Health MapsContact Email: gbacr@ucsf.eduSource Link: https://www.californiahealthmaps.org/?areatype=mssa&address=&sex=Both&site=AllSite&race=&year=05yr&overlays=none&choropleth=Obesity

Cancer Rates for Lake County Illinois. Explanation of field attributes: Colorectal Cancer - Cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine). This is a rate per 100,000. Lung Cancer – Cancer that forms in tissues of the lung, usually in the cells lining air passages. This is a rate per 100,000. Breast Cancer – Cancer that forms in tissues of the breast. This is a rate per 100,000. Prostate Cancer – Cancer that forms in tissues of the prostate. This is a rate per 100,000. Urinary System Cancer – Cancer that forms in the organs of the body that produce and discharge urine. These include the kidneys, ureters, bladder, and urethra. This is a rate per 100,000. All Cancer – All cancers including, but not limited to: colorectal cancer, lung cancer, breast cancer, prostate cancer, and cancer of the urinary system. This is a rate per 100,000.

Colorectal cancer is the third most common cancer diagnosed and third leading cause of cancer-related deaths in the United States for both men and women. The American Cancer Society (ACS) estimates about 108,070 new cases of colon cancer and 40,740 new cases of rectal cancer will be diagnosed, and about 49,960 deaths will occur as a result of this devastating disease in 2008. Over the last 20 years, the death rate for this cancer has been dropping as a result of screening and early detection of cancer. In 2007, ACS reported that early-stage colorectal cancer had a survival rate close to 80%, and up to 9,632 deaths could be prevented each year if eligible patients received screening when necessary. However, despite the proven efficacy of colorectal cancer (CRC) screening, only about 50% of eligible US patients are currently being screened. Specific Aims The central hypothesis of this proposal is that patient-initiated prompting of primary care physicians of the patient’s interest in screening will increase referrals for CRC screening. The following three areas will be investigated during this research: 1. To determine whether a communication tool provided to patients will initiate a conversation with their primary care physicians about CRC screening, especially via colonoscopy. 2. To determine whether this tool will impact referral patterns for screening, especially, although not primarily, among poor and underserved populations. 3. To determine whether differences exist in regard to patient-physician communication patterns about screening among residents and faculties in the fields of internal medicine and family practice clinics. At the close of the investigators study, the investigators wish to organize quantifiable data demonstrating how patient-initiated prompting of primary care physicians for CRC screening increases early detection and decreases potential mortality from colorectal cancer. This data will inform a second, larger study to pursue the questions surrounding patient-initiated prompting in

Colon Cancer Market Outlook

The global colon cancer market size was valued at approximately $15.2 billion in 2023, with a projected escalation to reach around $23.9 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.2%. One of the primary drivers of this growth is the increasing incidence of colon cancer worldwide, coupled with advancements in treatment modalities and diagnostic technologies. The aging global population, coupled with lifestyle changes and increasing awareness about early cancer screening, are significant contributors to this market's expansion. Moreover, the ongoing development of innovative therapies and the growing emphasis on personalized medicine are expected to further catalyze the market growth over the forecast period.

The rising prevalence of colon cancer is a major growth factor for this market. Colon cancer, also known as colorectal cancer, is the third most common cancer globally. Factors such as unhealthy dietary habits, sedentary lifestyles, obesity, and smoking are contributing to the increasing incidence of colon cancer. Moreover, advancements in healthcare infrastructure, particularly in developing countries, are facilitating improved access to cancer screening and treatment, thereby driving market growth. Additionally, government initiatives and awareness programs aimed at promoting regular screenings and early detection are playing a crucial role in increasing the demand for colon cancer diagnostic and treatment services.

Technological advancements in diagnostic and therapeutic procedures are significantly propelling market growth. The introduction of minimally invasive surgical techniques and advancements in radiation therapy and chemotherapy have improved the survival rates and quality of life of colon cancer patients. Furthermore, the advent of targeted therapy and immunotherapy is revolutionizing cancer treatment by offering more effective and personalized options. These therapies are showing promising results in terms of efficacy and reduced side effects, thereby increasing their adoption rates. Such innovations are expected to continue driving the market growth during the forecast period.

The increasing focus on research and development activities by pharmaceutical companies is another crucial growth driver. Companies are investing heavily in the development of novel drugs and therapies, with many new products currently in the pipeline. The approval of new therapies by regulatory authorities further boosts the market by providing patients with more advanced treatment options. Strategic collaborations and partnerships among key players to enhance their product portfolios and expand their geographic presence are also contributing to the market's growth. These efforts are expected to result in the introduction of more effective and affordable treatment solutions, thereby augmenting the market size.

Rectal Cancer Therapeutics have gained significant attention in recent years, particularly due to the unique challenges and treatment requirements associated with rectal cancer compared to other forms of colorectal cancer. The development of specialized therapeutic approaches, including neoadjuvant chemoradiotherapy and advanced surgical techniques, has been pivotal in improving patient outcomes. These therapies are tailored to address the specific anatomical and biological characteristics of rectal cancer, often involving a multidisciplinary approach to optimize treatment efficacy and minimize complications. The integration of novel therapeutic agents and precision medicine strategies is further enhancing the management of rectal cancer, offering hope for improved survival rates and quality of life for patients.

Regionally, North America held the largest share of the colon cancer market in 2023, driven by factors such as high healthcare expenditure, advanced healthcare infrastructure, and the presence of leading industry players. Europe followed closely, with a significant market share owing to increasing government initiatives and a growing emphasis on research and development. The Asia Pacific region is anticipated to witness the fastest growth during the forecast period, attributed to rising awareness about cancer screening, improving healthcare facilities, and a growing patient population. Moreover, increasing investments by key players in emerging economies and supportive government policies are expected to further drive the market growth in this region.

Treatment Type Analysis

Legacy unique identifier: P00225

The global colon and rectal carcinoma treatment market is experiencing robust growth, driven by rising incidence rates of these cancers, an aging global population, and advancements in treatment modalities. The market's size in 2025 is estimated at $50 billion, reflecting a substantial increase from previous years. A Compound Annual Growth Rate (CAGR) of 7% is projected from 2025 to 2033, indicating a consistently expanding market. Key drivers include the increasing adoption of advanced therapies like targeted therapies, immunotherapy, and minimally invasive surgical techniques, leading to improved patient outcomes and survival rates. Furthermore, rising awareness campaigns, better diagnostic capabilities, and expanding access to healthcare services in developing economies contribute to market expansion. However, the high cost of novel therapies, treatment-related side effects, and challenges in early detection in certain regions pose significant restraints on market growth. The market is segmented by application (hospital, clinic) and type of cancer (colon carcinoma, rectal carcinoma). Major players like Pfizer, Bayer Healthcare, Spectrum, Novartis, Amgen, Roche, and Merck are heavily invested in research and development, driving innovation and competition in the space. The North American market currently holds the largest share due to high healthcare expenditure and advanced infrastructure, but regions like Asia Pacific are experiencing rapid growth owing to increasing awareness and improving healthcare systems. The forecast period (2025-2033) anticipates consistent growth fueled by ongoing advancements in treatment approaches, such as personalized medicine and improved combination therapies. The continued rise in colorectal cancer incidence, particularly in developing nations, will further stimulate demand. However, ensuring equitable access to cutting-edge treatments across different socioeconomic groups remains a critical challenge. Future growth will depend on continued investment in research, the development of more effective and less toxic treatments, and the expansion of healthcare infrastructure globally. The competitive landscape will continue to be shaped by strategic partnerships, mergers and acquisitions, and the introduction of innovative therapies by pharmaceutical companies. Focus on early detection programs and preventative measures could significantly impact the market trajectory in the long term.